Publications
Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein Institute of Tropical Medicine
Our knowledge of the binding sites for neutralizing Abs (NAb) that recognize a broad range of HIV-1 strains (bNAb) has substantially increased in recent years. However, gaps remain in our understanding of how to focus B cell responses to vulnerable conserved sites within the HIV-1 envelope glycoprotein (Env). In this article, we report an immunization strategy composed of a trivalent HIV-1 (clade B envs) DNA prime, followed by a SIVmac239 ...
Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility Institute of Tropical Medicine
A broadly neutralizing monoclonal antibody targeting hepatitis C virus prevents viral infection in vitro and in uPA/SCID mice with humanized liver Ghent University
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo Institute of Tropical Medicine Ghent University
Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, resulting in accelerated progression of liver disease. Although the efficacy of HCV treatment using direct-acting ...
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers KU Leuven
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization KU Leuven
Symptomatic severe acute respiratory syndrome Coronavirus 2 reinfection of a healthcare worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response University of Antwerp Institute of Tropical Medicine
Neutralizing antibody response and antibody-dependent cellular cytotoxicity in HIV-1-infected individuals from Guinea-Bissau and Denmark Institute of Tropical Medicine
The development of therapeutic and prophylactic HIV vaccines for African countries is urgently needed, but the question of what immunogens to use needs to be answered. One approach is to include HIV envelope immunogens derived from HIV-positive individuals from a geographically concentrated epidemic with more limited viral genetic diversity for a region-based vaccine. To address if there is a basis for a regional selected antibody vaccine, we ...